Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination

Berto, Martina Boscolo; Spano, Giancarlo; Wagner, Benedikt; Bernhard, Benedikt; Häner, Jonas; Huber, Adrian Thomas; Gräni, Christoph

doi:10.1016/j.hlc.2021.06.521

Cited by 21 publications

(33 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We do not agree with the statement that the index case represents the first case with SARS-CoV-2 vaccination-induced TTS [ 1 ]. SARS-CoV-2 vaccination-induced TTS has previously been reported in at least four other cases ( Table 1 ) [ [2] , [3] , [4] , [5] ].…”

contrasting

confidence: 77%

“…We read with interest the case report by Boscolo Berto et al. about a 63-year-old female who developed the classical type of Takotsubo cardiomyopathy (TTS) one day after her first jab of the Moderna vaccine [ 1 ]. The patient completely recovered without any treatment [ 1 ].…”

mentioning

confidence: 99%

“…about a 63-year-old female who developed the classical type of Takotsubo cardiomyopathy (TTS) one day after her first jab of the Moderna vaccine [ 1 ]. The patient completely recovered without any treatment [ 1 ]. The study is appealing but raises several comments and concerns.…”

mentioning

confidence: 99%

“… Age Sex Brand LAOT TTS Type Treatment Outcome Reference 63 F 1. Moderna 1 d Classical None nr [ 1 ] 72 M 1. AZV 4 d Classical Dual APT CR [ 2 ] 65 F 1.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Letter to the Editor Regarding: What Triggers Takotsubo After a SARS-CoV-2 Vaccination? Heart Lung Circ. 2021;30(12):e119–20

Finsterer

Stöllberger

2022

Heart, Lung and Circulation

View full text Add to dashboard Cite

contrasting

confidence: 77%

mentioning

confidence: 99%

mentioning

confidence: 99%

“… Age Sex Brand LAOT TTS Type Treatment Outcome Reference 63 F 1. Moderna 1 d Classical None nr [ 1 ] 72 M 1. AZV 4 d Classical Dual APT CR [ 2 ] 65 F 1.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Letter to the Editor Regarding: What Triggers Takotsubo After a SARS-CoV-2 Vaccination? Heart Lung Circ. 2021;30(12):e119–20

Finsterer

Stöllberger

2022

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…We thank Finsterer and Stollberger [ 1 ] for their interest in our case report of Takotsubo cardiomyopathy (TCM) after the first injection of two mRNA-1273 (Moderna, Cambridge, MA, USA) COVID-19 vaccinations [ 2 ], and for the interesting questions raised. We are pleased to comment on their concerns raised that our case report might not be the first described in the literature.…”

mentioning

confidence: 99%

Reply: Takotsubo Cardiomyopathy After Receiving mRNA COVID-19 Vaccination is Very Rare

Gräni

2022

Heart, Lung and Circulation

Self Cite

View full text Add to dashboard Cite

Takotsubo syndrome and vaccines: a systematic review

Li,

Peddibhotla

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsTakotsubo syndrome (TTS) is a rare complication of vaccination. In this study, we sought to provide insight into the characteristics of reported TTS induced by vaccination.Methods and resultsWe did a systematic review, searching PubMed, Embase, Web of Science, Ovid MEDLINE, Journals@Ovid, and Scopus databases up to 26 April 2023 to identify case reports or case series of vaccine‐induced TTS. We then extracted and summarized the data from these reports. Eighteen reports were identified, with a total of 19 patients with TTS associated with vaccinations. Of the 19 included patients, the majority were female (n = 13, 68.4%) with a mean age of 56.6 ± 21.9 years. Seventeen patients developed TTS after coronavirus disease 2019 vaccination, 14 of whom received an mRNA vaccination. Two cases of TTS occurred after influenza vaccination. Among the 19 patients, 17 (89.5%) completed transthoracic echocardiography and 16 (84.2%) underwent angiography procedures. Seven patients (36.8%) completed cardiac magnetic resonance imaging. The median time to symptom onset was 2 (inter‐quartile range, 1–4) days. The most common symptoms were chest pain (68.4%), dyspnoea (57.9%), and digestive symptoms (31.6%). A total of 57.9% of patients developed nonspecific symptoms such as fatigue, myalgia, diaphoresis, and fever. Among the 16 reported cases of TTS, 15 patients (93.8%) exhibited elevated cardiac troponin levels, while among the nine reported cases, eight patients (88.9%) had elevated natriuretic peptide levels. All patients had electrocardiographic changes: ST‐segment change (47.1%), T‐wave inversion (58.8%), and prolonged corrected QT interval (35.3%). The most common TTS type was apical ballooning (88.2%). Treatment during hospitalization typically included beta‐blockers (44.4%), angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers (33.3%), and diuretics (22.2%). After treatment, 81.3% of patients were discharged with improved symptoms. Among this group, nine patients (56.3%) were reported to have recovered ventricular wall motion during follow‐up. Two patients (12.5%) died following vaccination without resuscitation attempts.ConclusionsTTS is a rare but potentially life‐threatening complication of vaccination. Typical TTS symptoms such as chest pain and dyspnoea should be considered alarming symptoms, though nonspecific symptoms are common. The risks of such rare adverse events should be balanced against the risks of infection.

show abstract

Takotsubo Cardiomyopathy After mRNA COVID-19 Vaccination

Cited by 21 publications

References 4 publications

Letter to the Editor Regarding: What Triggers Takotsubo After a SARS-CoV-2 Vaccination? Heart Lung Circ. 2021;30(12):e119–20

Letter to the Editor Regarding: What Triggers Takotsubo After a SARS-CoV-2 Vaccination? Heart Lung Circ. 2021;30(12):e119–20

Reply: Takotsubo Cardiomyopathy After Receiving mRNA COVID-19 Vaccination is Very Rare

Takotsubo syndrome and vaccines: a systematic review

Contact Info

Product

Resources

About